Charles River Laboratories International, Inc. CRL
We take great care to ensure that the data presented and summarized in this overview for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRL
View all-
Vanguard Group Inc Valley Forge, PA6.05MShares$1.34 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY5.17MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA2.09MShares$464 Million0.03% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA1.88MShares$416 Million1.21% of portfolio
-
Clearbridge Investments, LLC New York, NY1.51MShares$335 Million0.34% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.32MShares$293 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.19MShares$263 Million0.03% of portfolio
-
Nat Simons Meritage Group LP | San Francisco, Ca1.18MShares$262 Million7.54% of portfolio
-
Allspring Global Investments Holdings, LLC1.12MShares$248 Million0.49% of portfolio
-
Ariel Investments, LLC Chicago, IL933KShares$207 Million2.69% of portfolio
Latest Institutional Activity in CRL
Top Purchases
Top Sells
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Transactions at CRL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
George Massaro Director |
SELL
Open market or private sale
|
Direct |
332
-1.82%
|
$78,020
$235.7 P/Share
|
May 13
2024
|
Virginia M Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+12.36%
|
$127,452
$228.41 P/Share
|
May 13
2024
|
Nancy C Andrews Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+15.63%
|
$127,452
$228.41 P/Share
|
May 13
2024
|
Martin Mackay Director |
BUY
Grant, award, or other acquisition
|
Direct |
931
+3.64%
|
$212,268
$228.41 P/Share
|
May 13
2024
|
Craig B. Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+27.59%
|
$127,452
$228.41 P/Share
|
May 13
2024
|
Richard F Wallman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,019
+2.14%
|
$232,332
$228.41 P/Share
|
May 13
2024
|
Reshema Kemps Polanco Director |
BUY
Grant, award, or other acquisition
|
Direct |
844
+32.67%
|
$192,432
$228.41 P/Share
|
May 13
2024
|
Robert J Bertolini Director |
BUY
Grant, award, or other acquisition
|
Direct |
953
+1.44%
|
$217,284
$228.41 P/Share
|
May 13
2024
|
George Llado Sr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
865
+11.95%
|
$197,220
$228.41 P/Share
|
May 13
2024
|
George Massaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+8.29%
|
$127,452
$228.41 P/Share
|
May 13
2024
|
Deborah Turner Kochevar Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+6.61%
|
$127,452
$228.41 P/Share
|
May 10
2024
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Open market or private sale
|
Direct |
1,304
-5.31%
|
$294,704
$226.97 P/Share
|
May 02
2024
|
Flavia Pease Corporate Executive VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-10.03%
|
$207,176
$232.69 P/Share
|
Mar 08
2024
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
808
-10.32%
|
$215,736
$267.52 P/Share
|
Mar 04
2024
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,750
-13.93%
|
$717,750
$261.12 P/Share
|
Mar 01
2024
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
SELL
Bona fide gift
|
Indirect |
412
-1.53%
|
-
|
Feb 29
2024
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
SELL
Open market or private sale
|
Direct |
3,786
-22.43%
|
$957,858
$253.72 P/Share
|
Feb 29
2024
|
Victoria L Creamer EVP & Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,000
-26.95%
|
$1,265,000
$253.7 P/Share
|
Feb 22
2024
|
William D Barbo Corporate Executive VP & CCO |
SELL
Open market or private sale
|
Indirect |
4,050
-15.04%
|
$1,004,400
$248.5 P/Share
|
Feb 16
2024
|
James C Foster Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
4,000
-1.75%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 64.3K shares |
---|---|
Exercise of conversion of derivative security | 50.9K shares |
Open market or private purchase | 7.94K shares |
Payment of exercise price or tax liability | 37.6K shares |
---|---|
Open market or private sale | 49.2K shares |
Bona fide gift | 7.34K shares |